Circulation
- JI L, Zhang H
Letter by Ji and Zhang Regarding Article, "Rivaroxaban for 18 Months Versus 6
Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An
Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)".
Circulation. 2025;152:e90-e91.
- HE Z, Wang C, Tian H
Letter by He et al Regarding Article, "Rivaroxaban for 18 Months Versus 6 Months
in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label,
Multicenter, Randomized Clinical Trial (ONCO PE Trial)".
Circulation. 2025;152:e88.
- LIU G, Fu C, Xie J
Letter by Liu et al Regarding Article, "Rivaroxaban for 18 Months Versus 6 Months
in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label,
Multicenter, Randomized Clinical Trial (ONCO PE Trial)".
Circulation. 2025;152:e92-e93.
- SANTINI P, Pola R
Letter by Santini and Pola Regarding Article, "Rivaroxaban for 18 Months versus 6
Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An
Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)".
Circulation. 2025;152:e89.
- YAMASHITA Y, Morimoto T, Kimura T
Response by Yamashita et al to Letter Regarding Article, "Rivaroxaban for 18
Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary
Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)".
Circulation. 2025;152:e94-e95.
J Vasc Surg Venous Lymphat Disord
- KAMADA K, Fukaya E, Iwata E, Uchida D, et al
Disaster-associated Venous Thromboembolism Countermeasures in Japan: Insights
from Past Major Earthquakes.
J Vasc Surg Venous Lymphat Disord. 2025 Sep 9:102312.
PLoS Comput Biol
- ROOPNARINESINGH R, Jani ND, Leppert M, Mukherjee D, et al
Understanding thromboembolus transport patterns in the brain for stroke in the
presence of carotid artery stenosis.
PLoS Comput Biol. 2025;21:e1013269.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016